Milestone’s CARDAMYST Added to Express Scripts National Formularies Effective March 27, 2026
Express Scripts added CARDAMYST nasal spray to its commercial national formularies effective March 27, 2026, making Milestone’s self-administered PSVT treatment accessible to millions of commercially insured patients nationwide. This marks the first major PBM acceptance for CARDAMYST, expected to drive revenue growth as coverage negotiations with other payors continue.
1. Express Scripts Formulary Inclusion
Effective March 27, 2026, Express Scripts placed CARDAMYST (etripamil) nasal spray on its commercial national formularies, expanding coverage to commercially insured members across the United States. This is the first contracted formulary acceptance of CARDAMYST by a major pharmacy benefit manager, marking a pivotal commercial milestone for Milestone Pharmaceuticals.
2. Impact on Patient Access and Commercial Uptake
Inclusion on a national formulary greatly enhances patient affordability and access for the estimated two million U.S. adults with paroxysmal supraventricular tachycardia (PSVT). Milestone expects prescriptions and revenue to ramp up as the company engages additional insurers and drives broader adoption among healthcare providers.
3. CARDAMYST Product Profile and Pipeline
CARDAMYST is the first FDA-approved self-administered nasal spray for conversion of acute PSVT to sinus rhythm in adults, offering rapid, on-demand symptom relief outside clinical settings. The drug completed a Phase 3 program for adult PSVT, with ongoing Phase 2 pediatric studies and Phase 3 trials for acute atrial fibrillation control in adults.